Heart Failure: Expanding Destination Therapy - What Can We Expect in the Future?
WebcastFaculty
OVERVIEW
Heart Failure: Expanding Destination Therapy - What Can We Expect in the Future is organized by Baptist Health South Florida and will be held from Feb 01, 2018 - Feb 01, 2020.
The target audience for this medical event is Cardiologists, cardiovascular surgeons, interventional cardiologists, interventional radiologists, general internists, intensivists, critical care physicians, emergency medicine physicians, hospitalists, nurses, nurse practitioners, physician assistants, pharmacists and other interested healthcare providers. This CME Conference has been approved for a maximum of 1.25 AMA PRA Category 1 Credits.
Course Description :
Despite many medical advances and overall improving outcomes, end stage heart failure (HF) is inevitable for some patients. While experimentation continues towards medical and biologic interventions aimed at end-stage HF, by far the greatest progress has been made in mechanical circulatory support, which is now a potential option to a wide range of patients. This success has been a long time in coming but, it has now reached a critical stage where therapeutic success of Left Ventricular Assist Devices (LVADs) make them an increasingly viable option in the non-transplant candidate. Dr. Robert L. Kormos will discuss requirements and regulations to support management of end-stage heart failure (HF) for the non-transplant candidate to improve patient outcomes.
Learning Objectives :
• Discuss the key indications, risk factors for survival and adverse events for destination therapy for the management of end-stage heart failure (HF).
• List key elements of institutional infrastructure to support HF destination therapy and regulatory requirements to perform HF destination therapy.
• Implement strategies to support management of end-stage heart failure (HF) for the non-transplant candidate, and improve patient outcomes.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Cardiologists, cardiovascular surgeons, interventional cardiologists, interventional radiologists, general internists, intensivists, critical care physicians, emergency medicine physicians, hospitalists, nurses, nurse practitioners, physician assistants, pharmacists and other interested healthcare providers. This CME Conference has been approved for a maximum of 1.25 AMA PRA Category 1 Credits.
Course Description :
Despite many medical advances and overall improving outcomes, end stage heart failure (HF) is inevitable for some patients. While experimentation continues towards medical and biologic interventions aimed at end-stage HF, by far the greatest progress has been made in mechanical circulatory support, which is now a potential option to a wide range of patients. This success has been a long time in coming but, it has now reached a critical stage where therapeutic success of Left Ventricular Assist Devices (LVADs) make them an increasingly viable option in the non-transplant candidate. Dr. Robert L. Kormos will discuss requirements and regulations to support management of end-stage heart failure (HF) for the non-transplant candidate to improve patient outcomes.
Learning Objectives :
• Discuss the key indications, risk factors for survival and adverse events for destination therapy for the management of end-stage heart failure (HF).
• List key elements of institutional infrastructure to support HF destination therapy and regulatory requirements to perform HF destination therapy.
• Implement strategies to support management of end-stage heart failure (HF) for the non-transplant candidate, and improve patient outcomes.
Additional details will be posted as soon as they are available.
SPECIALITIES
CardiologyRELATED ONLINE COURSES
Quick Links